Clinical trials: HPV Vaccines
Papillomavirus Vaccines, Human Immunodeficiency Virus
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection.
- Conditions
- Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology
- Trial name
- AGO-Gard (NCT05266898)
- Testing
- Human papillomavirus 9-valent vaccine, recombinant, human papillomavirus vaccine, recombinant
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm
Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study
This study is extending follow up of women who participated in the Costa Rica Vaccine Trial (CVT) and received one dose or two doses of the human papillomavirus (HPV) vaccine, along with a group of women who received three doses.
- Trial name
- NCT03309033
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- Costa Rica
- Volunteers
- 946 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Dengue Fever
Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years
The purpose of the study is to demonstrate the non-inferiority (NI) of the immune response to 2 doses of 9vHPV vaccine, 1 co-administered with TDV, compared with 2 doses of 9vHPV vaccine administered alone.
- Trial name
- NCT04313244
- Testing
- 9vHPV Vaccine, Dengue Tetravalent Vaccine (TDV)
- Where
- 4 sites in Thailand
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- Takeda
Cervical Intraepithelial Neoplasia, Cervical Cancer
Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine
This is a Phase III clinical trial of the novel recombinant HPV 16/18 bivalent vaccine manufactured by Xiamen Innovax Biotech CO., LTD.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT01735006
- Testing
- HPV Vaccine, HEV vaccine
- Where
- China
- Volunteers
- 7,372 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Human Papilloma Virus, Warts
Intralesional HPV Vaccine for Condylomata
This study will investigate whether injecting genital warts with small quantities of the Gardasil 9 vaccine has an effect on the warts.
- Conditions
- Human Papilloma Virus, Warts, Warts, Genital, Condyloma
- Trial name
- NCT05087849
- Testing
- nonavalent human papillomavirus vaccine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Genital Wart, Penile Cancer
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Human Papillomavirus (HPV) Recombinant Vaccine (Hansenula Polymorpha) in Chinese male…
- Conditions
- Genital Wart, Penile Cancer, Anal Cancer, PIN-1
- Trial name
- NCT06465914
- Testing
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- 5 sites in China
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Human Papillomavirus (HPV) Vaccine, Human Papillomavirus (HPV) Vaccines
Strengthening HPV Vaccination and Adolescent Health Research Program in Nigeria (SHARP)
The goal of this clinical trial is to learn whether adding adolescent health services to routine government health programs can increase Human Papillomavirus (HPV) vaccination coverage among 9-year-old girls and improve use of…
- Conditions
- Human Papillomavirus (HPV) Vaccine, Human Papillomavirus (HPV) Vaccines, Human Papillomavirus (HPV) Infections, Adolescent Health Services
- Trial name
- SHARP (NCT07200414)
- Testing
- Integrated Adolescent Health Package, Routine Government Health Services
- Where
- Nigeria
- Volunteers
- 12,654 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cervical Intraepithelial Neoplasia, Cervical Cancer
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
This phase III clinical study was designed to evaluate the efficacy,immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD.…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Condylomata Acuminata
- Trial name
- NCT04537156
- Testing
- Nonavalent HPV vaccine, Bivalent HPV vaccine
- Where
- 2 sites in China
- Volunteers
- 9,327 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Infections, Papillomavirus
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current phase 3b study is designed to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV…
- Trial name
- NCT00552279
- Testing
- Cervarix TM
- Where
- 16 sites in Italy, Romania and 1 more
- Volunteers
- 805 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV-positive Oropharyngeal Squamous Cell Carcinoma
Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC
This phase I, open-label, single-arm trial uses a "3+3" dose-escalation design to evaluate the safety, tolerability, and preliminary efffcacy of intranasal WSK-IM05 vaccine combined with tislelizumab as neoadjuvant therapy in…
- Trial name
- NCT07565740
- Testing
- WSK-IM05 (4×10^10 vp), WSK-IM05 (8×10^10 vp), WSK-IM05 (1.6x10^11 vp)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Patient Compliance
Human Papilloma Viruses (HPV) Vaccine Adherence Community Clinic Study
There has been very limited research that has looked at electronic reminders (text messages) and its effectiveness in adherence to vaccination among low-income minority populations.
- Trial name
- NCT01908517
- Testing
- HPV Vaccine Electronic Reminders
- Where
- 2 sites in United States
- Volunteers
- 522 people, healthy volunteers welcome
- Sponsor
- East Carolina University
Infections, Papillomavirus
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 580299/008 and received the control vaccine (Hepatitis A vaccine).
- Trial name
- NCT00799825
- Testing
- GSK Biological's HPV vaccine GSK580299 (Cervarix™)
- Where
- 48 sites in United States, Canada
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Condylomata Acuminata
An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)
This study was conducted to demonstrate that Gardasil™ (quadrivalent human papillomavirus [qHPV] vaccine) 1) is well tolerated in young men, 2) reduces incidence of external genital lesions in young men, 3) reduces the incidence…
- Trial name
- NCT00090285
- Testing
- (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 4,065 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Vaccination Intent
Conversations With AI Chatbots Increase Short-Term Vaccine Intentions But Do Not Outperform Standard Public Health Messaging
The goal of this clinical trial is to test whether short conversations with large language model (LLM) chatbots can persuade vaccine-hesitant parents to vaccinate their children against human papillomavirus (HPV).
- Trial name
- NCT07132125
- Testing
- Default-style LLM chatbot, Conversational-style LLM chatbot, Public health informational materials
- Where
- United States
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Papillomavirus Infections
A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)
Researchers want to learn if V503 (also called the 9-valent human papillomavirus [9vHPV] vaccine, recombinant) can induce an immune response to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Chinese females who previously…
- Trial name
- NCT07785843
- Testing
- V503
- Where
- China
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Background: Recurrent respiratory papillomatosis (RRP) is a rare disease that causes wart-like growths called papillomas to grow in the airway, most often in the voice box, windpipe, or lungs.
- Conditions
- Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV), Papillomavirus Infection, Laryngeal Diseases
- Trial name
- NCT07756840
- Testing
- PRGN-2012, Bevacizumab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Genital Warts
Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)
The primary purpose of the study is to test the safety of HPV Vaccine in Women
- Trial name
- FUTURE (NCT00517309)
- Testing
- V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years
- Volunteers
- 1,877 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cancer, HPV Associated Cancer
Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors
The primary objectives of this study are to increase HPV vaccination initiation and 3-dose completion among pediatric, adolescent, and young adult (PAYA) cancer survivors
- Trial name
- NCT05665543
- Testing
- GLAm app
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Human Papillomavirus Virus
Observational Follow up of Prior HPV Vaccinees
HPV vaccines have been included in the national immunisation schedule since 2008, firstly as the Cervarix vaccine which protects against two HPV types and in 2012 as the Gardasil vaccine which offers protection against a further…
- Trial name
- HPVfollowup (NCT02811068)
- Testing
- venepuncture
- Where
- 2 sites in United Kingdom
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Public Health England
Human Papillomavirus
Provider Recommendation and HPV Vaccination
In the United State, there are millions of US teens who are not vaccinated against the human papillomavirus (HPV) putting them at risk of getting HPV-related cancers.
- Trial name
- HPVV (NCT05365048)
- Testing
- Local Tailoring implementation strategy, Prescribed Strategy
- Where
- United States
- Volunteers
- 301,201 people
- Sponsor
- Kaiser Permanente